4D Molecular Therapeutics, Inc.FDMTEarnings & Financial Report
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the research and development of targeted adeno-associated virus (AAV) gene therapies. Its core product candidates address unmet medical needs in ophthalmology, cardiology, and pulmonary disease segments, serving global patient populations with rare and common hard-to-treat conditions.
FDMT Q4 FY2025 Key Financial Metrics
Revenue
$85.1M
Gross Profit
N/A
Operating Profit
$14.7M
Net Profit
$19.4M
Gross Margin
N/A
Operating Margin
17.3%
Net Margin
22.8%
YoY Growth
8508900.0%
EPS
$0.43
4D Molecular Therapeutics, Inc. Q4 FY2025 Financial Summary
4D Molecular Therapeutics, Inc. reported revenue of $85.1M (up 8508900.0% YoY) for Q4 FY2025, with a net profit of $19.4M (up 139.1% YoY) (22.8% margin).
Key Financial Metrics
| Total Revenue | $85.1M |
|---|---|
| Net Profit | $19.4M |
| Gross Margin | N/A |
| Operating Margin | 17.3% |
| Report Period | Q4 FY2025 |
4D Molecular Therapeutics, Inc. Annual Revenue by Year
4D Molecular Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $85.2M).
4D Molecular Therapeutics, Inc. Quarterly Revenue & Net Profit History
4D Molecular Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $85.1M | +8508900.0% | $19.4M | 22.8% |
| Q3 FY2025 | $90.0K | +2900.0% | $-56.9M | -63195.6% |
| Q2 FY2025 | $15.0K | +200.0% | $-54.7M | -364386.7% |
| Q1 FY2025 | $14.0K | -50.0% | $-48.0M | -342657.1% |
| Q4 FY2024 | $1.0K | +105.6% | N/A | N/A |
| Q3 FY2024 | $3.0K | -100.0% | $-43.8M | -1461433.3% |
| Q2 FY2024 | $5.0K | -97.9% | $-35.0M | -699060.0% |
| Q1 FY2024 | $28.0K | -90.6% | $-32.4M | -115717.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $28000 | $5000 | $3000 | $1000 | $14000 | $15000 | $90000 | $85.1M |
| YoY Growth | -90.6% | -97.9% | -100.0% | 105.6% | -50.0% | 200.0% | 2900.0% | 8508900.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $629.9M | $620.1M | $604.0M | $560.4M | $515.7M | $473.6M | $424.0M | $566.7M |
| Liabilities | $29.3M | $31.8M | $51.1M | $49.8M | $46.0M | $52.7M | $55.0M | $61.0M |
| Equity | $600.6M | $588.3M | $552.9M | $510.6M | $469.7M | $420.9M | $369.0M | $505.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-29.1M | $-30.2M | $-29.4M | $-134.6M | $-47.8M | $-43.4M | $-46.5M | $28.6M |